Phase IIB Clinical Trial of Voclosporin Successfully Achieves Primary Endpoint
Today Aurinia Pharmaceutical Company announced positive top-line results of a Phase IIB clinical study of voclosporin, a potential new therapy option for people with active lupus nephritis (lupus-related kidney disease). The study met its primary endpoint of achieving complete remission in a statistically significant number of study participants who received voclosporin. More details about this study are available through the company’s news release.
Sandra C. Raymond, President & Chief Executive Officer of the Lupus Foundation of America said the results of this study are a very positive development for people with lupus-related kidney disease.
“The results of this trial are welcomed and exciting news for people with lupus and their doctors who are eager to have more tolerable and effective treatment options. Lupus-related kidney disease is one of the most serious and potentially life-threatening complications of lupus, affecting up to 60 percent of people with this autoimmune disease.
“This trial of voclosporin is the first trial of a potential treatment for active lupus nephritis to reach its primary endpoint, offering hope to individuals with lupus that an improved quality of life can soon be achieved. We are excited for the potential that the data from this study represents and we are eager to learn more details of additional analysis as they become available.
“We look forward to the timely commencement of a Phase III trial; and, should the findings confirm this study, the addition of this regimen to the arsenal of treatments available to people who have waited far too long for medicines that improve the quality of their lives.”
The Lupus Foundation of America will continue to monitor developments with this trial and communicate information to our constituents as it becomes available.